AI Article Synopsis
- PARG is an enzyme that breaks down ADP-ribose polymers created by PARP enzymes, showing the need for balance in ADP-ribose metabolism.
- Recent research has highlighted the roles of PARP-1 and PARG in various cell processes and the potential for drug development targeting these enzymes for disease treatment.
- While PARP-1 is well-understood, PARG's functions are less clear, but efforts are ongoing to explore its role in conditions like inflammation, stroke, and cancer therapy.
Article Abstract
Poly (ADP-robose) glycohydrolase (PARG) is a catabolic enzyme that cleaves ADP-ribose polymers synthesized by members of the poly (ADP-ribose) polymerase (PARP) family of enzymes. The growing evidence supports the importance of a tight control of poly (ADP-ribose) metabolism by the two major enzymes, PARP-1 and PARG. Recent studies have advanced the understanding of PARPs' and PARG's functions in various cellular and physiological processes. In the last 10 years, homeostasis of poly (ADP-ribosyl)ation has been a target of pharmaceutical interventions for various pathologies. Although the polymer synthesizing enzyme PARP-1 has been well studied, the function of PARG remains largely unknown. However, a great effort has been made in recent years to delineate biological functions of PARG and to explore the therapeutical potentials of PARG inhibition in pathophysiological conditions such as inflammation, ischemia, stroke, and cancer chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2741/3329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!